 |
|
|
|
|
This fall, join the Society of Interventional Oncology (SIO) for the back-by-popular-demand SIO Master Class: Catheter Directed Therapy for the New IR/IO Practice, taking place November 2-3, 2019 at the Raddison Blue Hotel in Chicago, Illinois, USA.
Designed for interventional radiologists and interventional oncologists, this comprehensive day-and-a-half course will feature an interactive approach to catheter directed therapies, led by national experts within the field.
Join us at the SIO Master Class to gain new insights and learn best practices through case-based discussions, presentations, and hands-on workshops. You will walk away with the skills required to handle intricate challenges facing new IR/IO practices in today’s specialized and continuously-evolving environment.
Space is limited and available on a first-come, first-served basis. Register early to secure your spot.
 SIO Research Committee Chair, Dr. Martijn Meijerink of Amsterdam UMC, shares his perspective on his career in IO, his committee work, and the importance of SIO as the field grows.
“We hope to stimulate IO research and hereby promote quality, accessibility and global acceptance of our treatment methods in order to reduce complications and improve quality of life and outcome for the patients we treat.”
Check out the full article here!
<br
Share your science with hundreds of professionals in the global interventional oncology community: Submit an abstract to present at SIO2020, taking place 31 January–3 February 2020 in New Orleans, Louisiana!
 Abstracts due 4 October 2019 at 4:59pm ET.
Accepted abstract authors will be recognized on the Society of Interventional Oncology website and in the SIO mobile app. All accepted abstracts will also be eligible for a scientific award to be presented at SIO2020!
Looking for other reasons to attend SIO2020? SIO 2019 presented some of the industry's best programming to date, and SIO2020 is building off that momentum to offer even more!
SIO2020 will feature brand-new, cutting-edge presentations, including:
- Pioneers and New Frontiers (see where IO started and where it's going)
- Hypoxia
- Complex IO: Decision-Making
- Outpatient IO
- Sarcoma and Soft Tissue
- Venous Interventions
- Oligometastatic Disease and Oligoprogression
- SIO Meets the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR)
... while also featuring standard scientific topics that it's known for, such as:
- Hepatocellular Carcinoma
- Renal
- SIO Supported Research
- How I Do It Video Session
- Colorectal Liver Metastases
- Comparative Effectiveness
- Tumor Boards
Visit the SIO website to learn more, to submit your abstracts, and to register for the meeting.
| Promoted by |
|
|
|
 |
 Whether you attended SIO 2019 and want to look back at your favorite presentations or couldn’t join us in Boston and want to experience the content you missed, the SIO 2019 On Demand conference proceedings are a great purchase!
Session listings include the sub-sessions for each session title and the presenters for each topic. View speaker slides, videos, and pointer movements so you can follow along with the recorded presentations. (Abstract sessions and live cases are not included.)
Wait, it gets better! Conference Recordings are now FREE for SIO members. Join now to enjoy this and other great benefits.
To gain access to SIO 2019 On Demand: Click here
 |
|
OsteoCool™ indications have expanded! Learn more about treatment options for patients with painful bone metastases and benign bone tumors, such as osteoid osteoma. Learn about OsteoCool™.
Learn about OsteoCool™. |
|
British Journal of Pharmacology
Nitric oxide (NO) has broad and sometimes dichotomous roles in cancer. The effects of NO in tumors depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular cancer (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NO synthase (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co‐expression of iNOS with cyclooxygenase‐2 (COX‐2) may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacologic intervention. READ MORE |
|
Clinical & Experimental Metastasis
Metastatic spine disease (MSD) is a severe event in cancer patients. Experimental data indicate that bone metastasis is mostly mediated by blood flow-dependent, passive arrest of circulating tumor cells to the bone metastatic niche (BMN). Here, researchers have set out to test these experimental observations in a clinical, human setting to improve our understanding of MSD. 507 patients, treated on spinal metastases in our institution from 2005 to 2015 were retrospectively evaluated. Researchers identified 259 patients with accessible staging reports of the skeleton before and at initial diagnosis of MSD. Data analysis comprised localizations of bone metastases, underlying malignancy and time to development of MSD. Dissemination pattern of bone metastasis was correlated with red bone marrow (RBM) content of the respective bone as a measure of blood flow. READ MORE
Thoracic Cancer
The aim of this study was to investigate the influence of convolution kernel and iterative reconstruction on the diagnostic performance of radiomics and deep learning (DL) in lung adenocarcinomas. A total of 183 patients with 215 lung adenocarcinomas were included in this study. All CT imaging data was reconstructed with three reconstruction algorithms, each with two convolution kernels (bone and standard). A total of 171 nodules were selected as the training‐validation set, whereas 44 nodules were selected as the testing set. Logistic regression and a DL framework‐DenseNets were selected to tackle the task. READ MORE |
| Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year. Read more |
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure |
|
|
|
|
Advanced Materials
Chemoimmunotherapy by systemic administration of individual regimens suffers from inconsistent pharmacokinetics profiles, low tumor specificity, and severe side effects. Despite promising nanoparticle‐based codelivery approaches in therapeutics, the pathophysiological barriers of solid tumors are a hurdle for tumor accumulation and deep penetration of the drug‐loaded nanoparticles. A light‐inducible nanocargo for immunotherapy is reported. LINC is composed of a reduction‐responsive heterodimer of photosensitizer pheophorbide A and indoleamine 2,3‐dioxygenase 1 (IDO‐1) inhibitor, i.e., NLG919, and a light‐activatable prodrug of oxaliplatin. LINC administrated through intravenous injection is passively accumulated at the tumor site to generate near‐infrared fluorescence signal. READ MORE |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
